| Literature DB >> 30460060 |
Pihong Wei1, Te Wang2, Shulin Han3, Guifen Ma1, Shenqiang Gao1, Zaiqi Yang1.
Abstract
This study aimed to explore the potential genes and pathways associated with bupivacaine-induced apoptosis. Human neuroblastoma cell line SH-SY5Y was used in this study. The effect of bupivacaine on cell viability of SH-SY5Y was detected by Cell Counting Kit-8. Transcriptome sequencing was performed for SH-SY5Y cells that were treated and untreated with bupivacaine based on the HiSeq 4000 sequencing platform. The sequencing results were analyzed using bioinformatics methods, including differentially expressed genes (DEGs) identification, functional enrichment analysis, protein-protein interaction (PPI) network analysis and module analysis. The cell viability of SH-SY5Y cells decreased significantly after bupivacaine treatment (p < .01). Based on the HiSeq 4000 sequencing platform, we obtained a global overview of the transcriptome of SH-SY5Y treated with/without bupivacaine. Bioinformatics analysis identified 335 up-regulated and 294 down-regulated DEGs in bupivacaine group. They were significantly enriched in cell cycle-associated functions and pathways and cAMP signaling pathway. In the PPI network, proliferating cell nuclear antigen (PCNA), v-Akt murine thymoma viral oncogene homolog 3 (AKT3), cyclin-dependent kinase inhibitor 1A (CDKN1A) and cell division cycle 6 (CDC6) had high topology scores. Module analysis obtained two sub-network modules (cluster 1 and cluster 2). PCNA, CDC6, CDKN1A and AKT3 may play important roles in bupivacaine-induced apoptosis. Additionally, bupivacaine may also induce apoptosis via pathways of cell cycle and cAMP signaling pathway.Entities:
Keywords: Bupivacaine; differentially expressed gene; pathway; transcriptome sequencing
Year: 2017 PMID: 30460060 PMCID: PMC6138311 DOI: 10.1080/19768354.2017.1287774
Source DB: PubMed Journal: Anim Cells Syst (Seoul) ISSN: 1976-8354 Impact factor: 1.815
Figure 1.Effect of bupivacaine on cell viability of human neuroblastoma cell line SH-SY5Y. 0 mM: control group (not treated with bupivacaine); 1.0 mM: treated with 1.0 mM bupivacaine; and 1.5 mM: treated with 1.5 mM bupivacaine. ** p < .01 compared with control group.
The results of data filtering.
| Sample | Control_1 | Control_2 | Bupivacaine _1 | Bupivacaine _2 |
|---|---|---|---|---|
| Raw reads number | 28,263,528 | 27,443,982 | 28,274,506 | 28,092,912 |
| Raw bases number | 4,239,529,200 | 4,116,597,300 | 4,241,175,900 | 4,213,936,800 |
| Clean reads number | 27,659,392 | 26,923,806 | 27,769,440 | 27,561,998 |
| Clean reads rate (%) | 97.86 | 98.11 | 98.21 | 98.11 |
| Clean bases number | 4,148,908,800 | 4,038,570,900 | 4,165,416,000 | 4,134,299,700 |
| Low-quality reads number | 233,254 | 240,916 | 187,950 | 230,560 |
| Low-quality reads rate (%) | 0.82 | 0.88 | 0.67 | 0.82 |
| Adapter polluted reads number | 370,882 | 279,260 | 317,116 | 300,354 |
| Adapter polluted reads rate (%) | 1.31 | 1.02 | 1.12 | 1.07 |
| Raw Q30 bases rate (%) | 94.24 | 94.13 | 94.86 | 94.2 |
| Clean Q30 bases rate (%) | 94.73 | 94.73 | 95.37 | 94.77 |
| Ns reads number | 0 | 0 | 0 | 0 |
| Ns reads rate (%) | 0 | 0 | 0 | 0 |
Figure 2.The CC, BP and MF terms, and KEGG pathways enriched by (a and b) up-regulated and (c and d) down-regulated DEGs. The x-axis represents the number of enriched gene.
Figure 3.The PPI network constructed by the DEGs. White node stands for up-regulated gene and gray node stands for down-regulated gene.
The top 15 nodes with high topology scores that were calculated by three centrality methods.
| Symbol | Degree | Symbol | Betweenness | Symbol | Closeness |
|---|---|---|---|---|---|
| PCNA | 35 | PCNA | 9877.4795 | PCNA | 0.0408125 |
| TUBB4B | 20 | VCP | 6175.589 | HSPA5 | 0.0406685 |
| TUBB | 20 | AKT3 | 6111.1416 | AKT3 | 0.0406082 |
| CDKN1A | 19 | HSPA5 | 4892.837 | TUBB | 0.040533 |
| HSPA5 | 19 | PCSK1 | 4049.953 | TUBB4B | 0.040518 |
| VCP | 18 | TUBB | 3755.4736 | VCP | 0.0404956 |
| TUBA1B | 17 | KCNMA1 | 2987.0981 | TUBA1B | 0.0403538 |
| AKT3 | 17 | CDKN1A | 2955.5698 | CDKN1A | 0.0403389 |
| MCM3 | 15 | TUBB4B | 2805.5461 | FUS | 0.0403315 |
| CDC6 | 15 | FUS | 2766.349 | TUBA1A | 0.0403092 |
| TUBA1A | 15 | IGF2 | 2758.5251 | HDAC9 | 0.040287 |
| MCM7 | 15 | HDAC9 | 2656.2869 | HSPA6 | 0.0402278 |
| HDAC9 | 15 | NPY | 2652.3323 | SMARCA4 | 0.0401909 |
| ASF1B | 13 | CRHR1 | 2415.4155 | ASF1B | 0.0401761 |
| PLK2 | 13 | SYT1 | 2405.1887 | TBPL2 | 0.0401761 |
Figure 4.The sub-network module obtained from the PPI network. White node stands for up-regulated gene and gray node stands for down-regulated gene.
Figure 5.The CC, BP and MF terms, and KEGG pathways enriched by the DEGs of (a) cluster 1 and (b) cluster 2.